advertisement
Medical Treatment Editor's Selection
175 comments — showing 1 to 25 · all topics
Which glaucoma drug combinations work best together?
Miriam Kolko on: Efficacy and Drug Interactions of Glaucoma Medications: A Systematic Review and Component Network Meta-analysis IGR 25-3 | 2025
IOP lowering does not affect VF status in the short term, study finds
Boel Bengtsson & Anders Heijl on: Does the Visual Field Improve After Initiation of Intraocular Pressure Lowering in the United Kingdom Glaucoma Treatment Study? IGR 25-1 | 2025
Efficacy and safety of a fixed RKI-brimonidine combination
Kaweh Mansouri on: Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study IGR 24-4 | 2024
Do Prostaglandin Analogs prevent Functional Loss in Glaucoma Suspects?
Jonathan Crowston & Jess Tang on: Retinal Ganglion Cell Functional Recovery after Intraocular Pressure Lowering Treatment Using Prostaglandin Analogs in Glaucoma Suspects: A Prospective Pilot Study IGR 24-3 | 2024
Bimatoprost Implant and Circadian IOP
Kaweh Mansouri on: Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes IGR 24-1/2 | 2024
Neuroprotection
Keith Martin on: Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement IGR 23-4 | 2023
Impact of Low Vision on Medical Treatment
Andrew Tatham & Celia Alcalde on: Patients with Low-vision Struggle with Placing Eye Drops and Benefit from an Eye Drop Aid IGR 23-4 | 2023
Gene Therapy
Makoto Aihara on: Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma IGR 23-4 | 2023
Degradation of the bimatoprost implant
Ruchi Shah & Robert Feldman on: Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies IGR 23-3 | 2023
Can a selective EP2-antagonist avoid PAPS?
Niklas Telinius & Miriam Kolko on: Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need IGR 22-3 | 2022
A Phase 2 Neuroprotection Randomized Clinical Trial
Harry Quigley on: Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial IGR 22-3 | 2022
Effects of Prostaglandins on Eyelids
Cedric Schweitzer on: Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis IGR 22-2 | 2021
Multiple Therapy Slows Rate of Glaucoma Progression
Tony Realini on: The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial IGR 22-2 | 2021
ROCK Inhibitor Mechanism of Action
Makoto Araie on: Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study IGR 22-2 | 2021
Autologous Stem Cells for Visual Restoration
Thomas Johnson on: Mesenchymal stem and non-stem cell surgery, rescue, and regeneration in glaucomatous optic neuropathy IGR 22-2 | 2021
Natrsudil combinations
Makoto Aihara on: Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents IGR 22-1 | 2021
Netarsudil for Glaucoma
Andrew Tatham on: Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension IGR 21-4 | 2021
Bimatoprost Implant for Glaucoma
Esther Hoffmann on: Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) IGR 21-4 | 2021
Oral Acetazolamide affects both IOP and ICP
John Berdahl & Brian M. Shafer on: Intraocular and intracranial pressure in glaucoma patients taking acetazolamide IGR 21-3 | 2021
Neuroprotection in a Clinical Trial I
Jessica Tran & Louis Pasquale on: Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial IGR 21-3 | 2021
24-hour IOP monitoring
Sameh Mosaed on: Correlation Between Office-Hour and Peak Nocturnal Intraocular Pressure in Patients Treated with Prostaglandin Analogs IGR 21-2 | 2021
The Importance of Being Adherent
Adeleh Yarmohammadi & Sally Baxter on: The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study IGR 21-1 | 2020
The Importance of Being Adherent
Fotis Topouzis on: The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study IGR 21-1 | 2020
Mitotherapy in Glaucoma
Jonathan Crowston on: Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina IGR 21-1 | 2020
Mitotherapy in Glaucoma
Keith Martin on: Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina IGR 21-1 | 2020
Browse
This issue
advertisement
